Tweets
Digital biomarkers are also going to be useful int he future - from devices such as phone / watches.
Bella Mehta @bella_mehta ( View Tweet )
2 years ago
Great 1st #EULAR2024 scientific session: “Asymptomatic” Hyperuricemia — innocent bystander vs. menacing foe. Data re: effects on joints, kidneys, & heart have not supported clear clinical consequences w/ exception of kidney crystal deposition. TIGER Study results eagerly awaited. https://t.co/IPQU3Ww0NA
Links:
Tuhina Neogi, MD, PhD @Tuhina_Neogi ( View Tweet )
2 years ago
Final prep in my hotel room for tomorrow’s big #EULAR2024 opening debate: this David up against the metaphorical (if not physical) Goliath, @Janetbirdope.
Data does not adequately justify this JAKi regulatory safety warning, tomorrow I’ll tell you why. Details below ⬇️
@RheumNow https://t.co/rwFtYRlpLY
David Liew @drdavidliew ( View Tweet )
2 years ago
#EULAR204
Encouraging Timeline for future potential treatments for #SLE #Lupus
@LUPUSUK @LupusMadrid @Lupus_Chat @LupusEurope https://t.co/SLKc0XCtFq
Dr Gurdeep S Dulay @gurdeep_dulay ( View Tweet )
2 years ago
Reminder of relevance of #Rheumatoid factor
⬆️RF also predicts
cardiovascular events ⚠️
⬆️disease activity
❗️Worse outcomes
#EULAR2024 #RF #RA https://t.co/kXwh682ONp
Dr Gurdeep S Dulay @gurdeep_dulay ( View Tweet )
2 years ago
OP0048 Impressive CLASI (lupus skin index score) with #deucravacitinib - data presented by Dr C Arriens #EULAR24 @RheumNow #WiR https://t.co/EuQdwuolN6
TheDaoIndex @KDAO2011 ( View Tweet )
2 years ago
What is new in RA at #EULAR2024?
Below 👇🏻 my article summarising some of the exciting new MoA, therapeutic strategies and drugs that might (or not) shape RA future!
https://t.co/ttYdElWlBY
@RheumNow
Links:
Aurelie Najm @AurelieRheumo ( View Tweet )
2 years ago
🚨New(ish) MoA in RA
Abiprubart anti-CD40 mAb
Blocks T cell activation
Reduction DAS28-CRP Wk 12 -2.2 vs. -1.6 PBO
Small sample n=25 per gpe
Safety profile acceptable
To be continued...
Abstr#OP0036 #EULAR2024 @RheumNow https://t.co/su4L7A7nGJ
Aurelie Najm @AurelieRheumo ( View Tweet )
2 years ago
Substudy of SELECT-COMPARE trial
Week 60 immunogenicity RZV RA treated UPA 15 mg + MTX
✔️ HUmorale response 71%
✔️ Cellular response 65%
✔️ No serious AEs
✔️ One event of HZ occurred during follow up
Abstr#OP0020 #EULAR2024 @RheumNow https://t.co/8OMwGuIZFx
Aurelie Najm @AurelieRheumo ( View Tweet )
2 years ago
Novel B cell depleters! Bispecific T cell engagers (BiTEs) being studied for #SLE & #RA as a way to get CAR-T cell like responses but more accessible w/less risk for CK release syndrome. #EULAR24
T cell-engaging therapies — BiTEs and beyond | Nature Reviews Clinical Oncology
TheDaoIndex @KDAO2011 ( View Tweet )
2 years ago
I chaired great debate at #EULAR2025 - JAK Inhibitor Special Warnings: can observational data debunk an RCT? Drs Janet Pope(NO) vs David Liew(YES). Voting suggests most are concerned about JAK warnings, but Liew won by converting a minority his way @janetbirdope @Drdavidliew https://t.co/bV1JdO7c4e
Dr. John Cush @RheumNow ( View Tweet )
2 years ago
Nordic country analysis of mortality in RA (n 1145), RA-ILD (239), population ILD (378) & nl controls (1890) shows most mortality in pop ILD (HR 8.3), but less in RA-ILD (HR 3.6). Why is death less in latter; could it be RA therapies? Abstr #POS0022 # EULAR2025 https://t.co/wFZq49rIiW
Dr. John Cush @RheumNow ( View Tweet )
2 years ago
